Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Brancaccio Giuseppina, Coco Barbara, Nardi Alessandra, Quaranta Maria Giovanna, Tosti Maria Elena, Ferrigno Luigina, Cacciola Irene, Messina Vincenzo, Chessa Luchino, Morisco Filomena, Milella Michele, Barbaro Francesco, Ciancio Alessia, Russo Francesco Paolo, Coppola Nicola, Blanc Pierluigi, Claar Ernesto, Verucchi Gabriella, Puoti Massimo, Zignego Anna Linda, Chemello Liliana, Madonia Salvatore, Fagiuoli Stefano, Marzano Alfredo, Ferrari Carlo, Lampertico Pietro, Di Marco Vito, Craxì Antonio, Santantonio Teresa Antonia, Raimondo Giovanni, Brunetto Maurizia R, Gaeta Giovanni Battista, Kondili Loreta A, PITER collaborating investigators
Аннотация
METHODS: A cross-sectional, multicenter, observational cohort (PITER cohort) of consecutive patients with hepatitis B surface antigen (HBsAg) over the period 2019-2021 from 46 centers was evaluated. The reference was the MASTER cohort collected over the years 2012-2015. Standard statistical methods were used.
RESULTS: The PITER cohort enrolled 4583 patients, of whom 21.8% were non-Italian natives. Compared with those in MASTER, the patients were older and more often female. The prevalence of hepatitis B e antigen (HBeAg) declined (7.2% vs 12.3; P <0.0001) and that of anti-hepatitis D virus (HDV) remained stable (9.3% vs 8.3%). In both cohorts, about 25% of the patients had cirrhosis, and those in the PITER cohort were older. HBeAg-positive was 5.0% vs 12.6% (P <0.0001) and anti-HDV positive 24.8% vs 17.5% (P <0.0017). In the logistic model, the variables associated with cirrhosis were anti-HDV-positive (odds ratio = 10.08; confidence interval 7.63-13.43), age, sex, and body mass index; the likelihood of cirrhosis was reduced by 40% in the PITER cohort. Among non-Italians, 12.3% were HBeAg-positive (vs 23.4% in the MASTER cohort; P <0.0001), and 12.3% were anti-HDV-positive (vs 11.1%). Overall, the adherence to the European Association for the Study of the Liver recommendations for antiviral treatment increased over time.
CONCLUSION: Chronic hepatitis B virus infection appears to be in the process of becoming under control in Italy; however, HDV infection is still a health concern in patients with cirrhosis and in migrants.